Premium
The role of oncoplastic breast reduction in the conservative management of breast cancer: Complications, survival, and quality of life
Author(s) -
AceaNebril Benigno,
CereijoGarea Carmen,
GarcíaNovoa Alejandra,
VarelaLamas Cristina,
BuilesRamírez Sergio,
BouzónAlejandro Alberto,
MosqueraOses Joaquín
Publication year - 2017
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.24550
Subject(s) - medicine , breast cancer , quality of life (healthcare) , mastectomy , mammaplasty , oncoplastic surgery , surgery , survival rate , radiation therapy , patient satisfaction , total mastectomy , cancer , retrospective cohort study , nursing
Background and Objectives Reduction Mammaplasty (RM) in breast cancer allows mammary remodeling after wide excisions. We aimed to analyze the complications, survival, and quality of life after RM. Methods Retrospective study of women who underwent a surgical intervention for breast cancer between 2000 and 2016. Patients were divided into two groups: RM and tumorectomy. Postoperative complications, survival and quality of life were assessed using the Breast‐Q questionnaire. Results A total of 801 patients were evaluated, with a mean follow up of 84 months. RM patients experienced a longer operating time and hospital stay, and a higher proportion of tissue necrosis compared to tumorectomy patients ( P < 0.001). No significant differences were observed regarding rate of re‐excision or rate of mastectomy, but the recurrence rate at 10 years was higher for RM patients ( P < 0.03). Patients who underwent RM reported optimal satisfaction with the breast and a good quality of life. Conclusions RM is a useful approach in breast cancer surgery, with a low rate of re‐excision and mastectomy. Overall survival at 10 years is similar to that associated with tumorectomy, though with a higher rate of local recurrence. Patient satisfaction and quality of life appears to be good one year after radiotherapy.